Clinical Trials
9 trialsNCT07615751 2026-05-29
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
Fudan University
Phase 3 Recruiting
NCT05582499 2026-05-28
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT07610720 2026-05-28
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07600164 2026-05-20
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
Peking University People's Hospital
Phase 4 Not yet recruiting
NCT06563999 2026-04-21
NUMER
Sun Yat-sen University
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT05769010 2026-04-01
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
Phase 2 Recruiting
NCT07335081 2026-03-24
ctDNA in HER2+ EBC Neoadjuvant Treatment
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06495541 2026-03-20
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
Tianjin Medical University Cancer Institute and Hospital
Phase NA Not yet recruiting